多过敏原致敏患者单过敏原与多过敏原舌下免疫治疗的初步研究
结果显示各组RCSS与m-RQLQ评分较基线均显著下降(p<0.05),但每日过敏药物使用数无显著减少(p=0.50),且不同过敏原数量组间无显著差异。提示在多过敏原致敏患者中,单抗原、少抗原与多抗原水剂SLIT疗效无显著差异。
要点
- 单抗原、少抗原与多抗原水剂SLIT均能显著改善过敏症状。
- 多过敏原致敏患者中不同过敏原数量SLIT疗效无显著差异。
- 每日过敏药物使用数在SLIT后无显著减少。
核心结论
- 单抗原、少抗原和多抗原水剂SLIT均显著改善过敏症状。
- 在多过敏原致敏患者中,单过敏原SLIT与少过敏原或多过敏原SLIT的疗效无显著差异。
研究设计与样本
- 受试者采用盲法随机分配至单过敏原(1种)、少过敏原(3种)或全部致敏过敏原(多过敏原)SLIT治疗组。
- 所选过敏原为患者致敏程度最高且与病史相关的过敏原。
主要发现
- 所有研究组在开始SLIT后各时间间隔(6周、3个月、6个月、9个月)的RCSS和m-RQLQ评分较基线均显著下降(p<0.05)。
- 无论治疗瓶中所含过敏原数量如何,每日过敏药物使用数均无显著下降(p=0.50)。
- 基于所用过敏原数量,未出现显著差异。
关键数值与推荐
- 主要结局包括每日过敏药物使用、每周鼻结膜炎症状评分(RCSS)和迷你鼻结膜炎生活质量问卷(m-RQLQ)。
- 所有指标在基线、6周、3个月、6个月和9个月进行测量。
临床怎么用
- 对于多过敏原致敏患者,选择单过敏原SLIT即可显著改善症状,无需增加过敏原数量。
- SLIT治疗期间应关注症状评分与生活质量改善,而非过敏药物使用数的减少。
局限性
- 研究未报告样本量计算或把握度分析。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Sublingual immunotherapy (SLIT) has emerged as an effective and exceptionally safe method of treatment of the atopic patient. However, the optimal number of allergens that should be included in the SLIT treatment regimen for the polysensitized patient is not known and practices vary widely. This study aims to compare the efficacy of single-allergen SLIT with pauci-allergen vs multiallergen aqueous SLIT in polysensitized patients. METHODS: Sixteen subjects sensitized to 6+ allergens were enrolled in the study. Subjects were blinded and randomized to SLIT treatment groups that included 1 (single), 3 (pauci), or all sensitized allergens (multi). Allergens selected were those to which the patient was most sensitized and correlated with history. Primary outcomes included daily allergy medication use, weekly Rhinoconjunctivitis Symptom Score (RCSS), and the mini-Rhinoconjuncitivitis Quality of Life Questionnaire (m-RQLQ). All metrics were measured at baseline, 6 weeks, 3 months, 6 months, and 9 months. RESULTS: There were significant decreases from baseline in RCSS and m-RQLQ scores in all study groups at each interval after beginning SLIT (p < 0.05). There was no significant decrease in number of daily allergy medications used regardless of number of allergens in patient's treatment vial (p = 0.50). No significant differences emerged based on number of allergens used. CONCLUSION: Single-antigen, pauci-antigen, and multiantigen aqueous SLIT significantly improved allergy symptoms. There was no significant difference observed in efficacy of single-allergen SLIT vs pauci-allergen or multi-allergen SLIT in polysensitized patients.
引用
- Ortiz AS, McMains KC, Laury AM, et al. Single vs multiallergen sublingual immunotherapy in the polysensitized patient: a pilot study. Int Forum Allergy Rhinol. 2018. PMID: 29377605. doi:10.1002/alr.22071
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。